Researchers Demonstrate Activity Of Mebendazole In Metastatic Melanoma

Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.

More: continued here

Filed under: Cancer on August 11th, 2008